Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343

Website: www.sunpharma.com CIN: L24230GJ1993PLC019050

**Date:** 31.03.2021

National Stock Exchange of India Ltd,

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

Scrip Name: SUNPHARMA

Dear Sir/ Madam,



BSE Ltd.,

Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001.

Scrip Code: 524715

## Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015.

We would like to inform you that our wholly owned Indian subsidiary's investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) has through its wholly-owned entity DigiHealth Technologies LLP, acquired 66.02% ownership interest in AIOCD Pharmasofttech Awacs Private Limited ("AWACS") though a combination of (i) direct purchase of 50% ownership interest in AWACS and (ii) indirect purchase of 16.02% ownership interest in AWACS through acquisition of 32.04% shareholding interest in Trikaal Mediinfotech Private Limited. It is also agreed to acquire the balance stake subject to fulfilment of certain terms and conditions.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated 9th September, 2015 are given in Annexure 1 to this letter.

We request you to kindly take this in your record and disseminate.

Thanking you,

Yours Sincerely

For Sun Pharmaceutical Industries Limited

[Ashok Bhuta] **Compliance Officer** 

Encl: As above

Sun House, Plot No. 201 B/1,

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com CIN: L24230GJ1993PLC019050



### <u>ANNEXURE – 1</u>

Details as per the Securities and Exchange Board of India circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No.	Particulars	Detail
a.	Name of the target entity, details in brief such as size, turnover etc.	(i) Name of the Target Entities:  AIOCD Pharmasofttech Awacs Private Limited ("AWACS").
		Trikaal Mediinfortech Private Limited ("Trikaal")
		(ii) Details of the Target Entities:
		AWACS is engaged in the business of pharmaceutical data collection and market research.
		Trikaal is 50% owner of AWACS and holds certain intellectual property in relation to AWACS's business.
b.	Whether the acquisition would fall within related party transaction(s)and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is one at "arms length"	Not a related party transaction.
c.	Industry to which the entity being	Healthcare Services
	acquired belongs	
d.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line' of business of the listed entity)	A step by ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) towards the initiative with an objective to facilitate, enable and promote efficiency and Good Distribution Practices ('GDP') including digitizing healthcare infrastructure in India, inter alia, in support of the National Digital Health Mission of Government of India ('Business'). The acquisition is and will be done by its wholly owned entity DigiHealth Technologies LLP.

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Sun House, Plot No. 201 B/1,

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343 Website: www.sunpharma.com CIN: L24230GJ1993PLC019050



Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
Indicative time period for completion of the acquisition	The acquisition of 66.02% of shareholding in AWACS (direct and indirect together) has been completed on 30 <sup>th</sup> of March, 2021.  The acquisition of 33.44% of the shareholding in AWACS (indirect) is envisaged to be completed over the course of next few months subject to fulfilment of certain terms and conditions.  The remaining 0.54% of the shareholding in AWACS (indirect) is likely to be acquired
Nature of consideration - whether cash consideration or share swap and details of the same	after 05 years (FY: 2026-'27)  Cash Consideration payable by DigiHealth Technologies LLP
Cost of acquisition or the price at which the shares are acquired	The cost of acquisition for the combined transaction of AWACS and Trikaal is approximately INR 75 crores for acquisition of 100% stake in AWACS and Trikaal (direct and indirect together).
Percentage of shareholding / control acquired and / or number of shares acquired	Please refer to the response provided in point f above.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	(i) About the entities:  AWACS is engaged in the business of pharmaceutical data collection and market research.  Trikaal is 50% owner of AWACS and holds certain intellectual property in relation to AWACS's business.  (ii) Date of Incorporation:  AWACS: September 21, 2007  Trikaal: January 03, 2007
	regulatory approvals required for the acquisition  Indicative time period for completion of the acquisition  Nature of consideration - whether cash consideration or share swap and details of the same  Cost of acquisition or the price at which the shares are acquired  Percentage of shareholding / control acquired and / or number of shares acquired  Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Sun House, Plot No. 201 B/1,

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324

Fax: (91-22) 4324 4343

Website: www.sunpharma.com CIN: L24230GJ1993PLC019050



(iii) Turnover history of last 3 years:
AWACS:
2019-2020: 15,31,95,103 2018-2019: 16,15,30,697 2017-2018: 16,30,86,020
Trikaal:
2019-2020: Nil 2018-2019: Nil 2017-2018: 1,10,00,000
(iv) Country: India